Physician profile
Leonard Alsfeld
NPI 1912346693
$90,899.31
in general payments reported to CMS, 2019-2025
21 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2022: $160 · 2023: $8,175 · 2024: $51K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $19K · Travel and Lodging: $7,873 · Food and Beverage: $2,908 · Education: $382 · Gift: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,212.50 |
| Consulting Fee | $19,228.40 |
| Travel and Lodging | $7,872.87 |
| Food and Beverage | $2,907.82 |
| Education | $382.18 |
| Gift | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $52,192.66 | 2023-2025 | Yescarta |
| Incyte Corporation | $25,631.58 | 2023-2025 | Niktimvo, Jakafi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $6,283.90 | 2024-2025 | |
| Cti Biopharma Corp. | $3,191.76 | 2023 | Vonjo |
| Amgen INC. | $1,372.00 | 2025 | Blincyto |
| National Marrow Donor Program | $1,359.32 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $165.95 | 2020-2025 | Enhertu |
| Abbvie INC. | $106.94 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $81.86 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Genmab U.S., INC. | $58.35 | 2024 | Epkinly |
| Beigene USA, INC. | $54.17 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $51.65 | 2022 | |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $41.27 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $40.18 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $29.91 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $29.08 | 2024 | |
| Morphosys, US INC. | $24.40 | 2023 | Monjuvi |
| Legend Biotech USA INC. | $20.93 | 2023 | Carvykti |
| Epizyme, INC. | $15.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Alsfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.